Trending News

Mesoblast (MESO) reports positive progress with FDA regarding two key products: Revascor® for heart failure and Ryoncil® for GvHD. The company held a Type B meeting with FDA under RMAT designation for Revascor®, achieving alignment on CMC, potency assays, and confirmatory trial design. For Ryoncil®, already FDA-approved for children with SR-aGvHD, Mesoblast plans to discuss a pivotal trial for adult treatment extension. Since its March 2025 launch, Ryoncil® has exceeded expectations with over 20 transplant centers onboarded and insurance coverage reaching 220 million US lives. By July 2025, all 51 States will provide Medicaid coverage, impacting 24 million lives. The commercial launch has shown strong physician adoption and hospital onboarding in the first ten weeks.

Chime, a leading fintech company, has announced the pricing of its IPO at $27.00 per share for 32 million shares of Class A common stock. The offering includes 25.9M shares from Chime and 6.1M shares from existing stockholders. Trading will commence on Nasdaq under ticker CHYM on June 12, 2025. The company granted underwriters a 30-day option for an additional 4.8M shares. Morgan Stanley, Goldman Sachs, and J.P. Morgan are leading the offering as book-running managers. The IPO is expected to close on June 13, 2025, subject to customary conditions. Notably, Chime will not receive proceeds from shares sold by existing stockholders.

Editas Medicine (NASDAQ: EDIT) reported promising preclinical data for its in vivo gene editing treatment for sickle cell disease and beta thalassemia. Using proprietary targeted lipid nanoparticle (tLNP) delivery, the company achieved 58% mean editing in hematopoietic stem cells (HSCs) at five months after a single dose in non-human primates, significantly exceeding the 25% threshold needed for therapeutic benefit. The treatment targets HBG1/2 promoters to increase fetal hemoglobin production, mimicking natural mechanisms. Notably, the biodistribution data showed significant liver de-targeting compared to standard LNPs. The data will be presented at the European Hematology Association 2025 Congress in Milan, Italy.

XPENG unveils upgraded versions of its G6 and G9 Ultra Smart SUVs for the European market, featuring groundbreaking 5C supercharging battery technology and 800V high-voltage SiC platform across all trims. The vehicles achieve exceptional charging speeds, reaching 10-80% SOC in just 12 minutes, with the G9 capable of 525 kW charging and G6 at 451kW. Both models showcase significant interior and exterior enhancements, including new color options like Stellar Purple for G6 and Black Edition for G9. The vehicles feature advanced intelligent driving technology, upgraded cockpits with Apple CarPlay & Android Auto support, and premium comfort features. The G6 introduces a new Super Star-Ring Interior Design with 60% cabin transformation, while the G9 offers luxury upgrades including a three-layer heat-insulating panoramic sunroof. European orders will open from mid-July across seven countries.

UCB and Biogen presented Phase 3 PHOENYCS GO study results for dapirolizumab pegol (DZP) in systemic lupus erythematosus (SLE) at EULAR 2025. The study demonstrated significant improvements in disease activity and fatigue symptoms. DZP showed superior FACIT-Fatigue scores (8.9 vs 5.2) compared to standard of care (SOC). At Week 48, 40.9% of DZP patients achieved low disease activity versus 19.6% with SOC alone, and 19.2% achieved DORIS remission compared to 8.4% with SOC. The safety profile was generally favorable, with 82.6% experiencing treatment-emergent adverse events in the DZP group versus 75% in SOC. A second Phase 3 trial (PHOENYCS FLY) is ongoing to confirm these results. DZP is not yet approved by any regulatory authority for SLE treatment.

Insmed announced the pricing of a public offering of 7,812,500 common stock shares at $96.00 per share, aiming to raise approximately $750 million in gross proceeds. The company granted underwriters a 30-day option to purchase up to 1,171,875 additional shares. The proceeds will fund research and development of brensocatib, pre-commercial activities, further development of ARIKAYCE, research for treprostinil palmitil inhalation powder (TPIP), INS1201, pre-clinical research, and general corporate purposes including business expansion. The offering, led by major financial institutions including Goldman Sachs, Leerink Partners, and others, is expected to close on June 13, 2025.

Autolus Therapeutics presented extended follow-up data from the FELIX study of obe-cel in relapsed/refractory B-ALL patients at the 2025 EHA Congress. The results showed impressive durability with median response duration of 42.6 months. At 24 months, over 50% of patients maintained remission, with 38% of ongoing responders requiring no additional therapy by month 33. The 24-month probability rates were 43% for Event Free Survival and 46% for Overall Survival. The study demonstrated obe-cel's effectiveness across age groups, with favorable outcomes in both under and over 55-year-old patients. Key factors associated with long-term remission included Philadelphia chromosome-positive disease, earlier obe-cel use, lower disease burden, and ongoing CAR T-cell persistence. No new safety concerns emerged during the extended follow-up period.

Uxin Limited (NASDAQ: UXIN), China's leading used car retailer, reported mixed Q1 2025 financial results. Transaction volume reached 8,264 units, down 12.4% QoQ but up 103.6% YoY. Total revenues were RMB504.2M (US$69.5M), decreasing 15.5% QoQ but increasing 58.0% YoY. The company maintained a 7.0% gross margin and reduced its operating loss to RMB35.3M (US$4.9M). Retail transaction volume was 7,545 units, showing strong YoY growth of 141.5% despite seasonal impact from Chinese New Year. The company's new Wuhan superstore began operations, and management expects Q2 2025 retail transaction volume to exceed 10,000 units. Non-GAAP adjusted EBITDA showed a loss of RMB8.9M, improving 78% YoY. The company faces liquidity challenges with current liabilities exceeding assets by RMB373.5M but maintains confidence in meeting obligations through planned financings and operational improvements.

Hexagon AB has announced the acquisition of APEI, a French aerial mapping company, to strengthen its geospatial data capabilities in Europe. APEI operates a private aircraft fleet for aerial data collection in France, neighboring European countries, and Africa, and has been a long-term Hexagon partner. The acquisition will support growing demand for geospatial content, particularly in France's large mapping market. APEI, with approximately 10 employees, will be integrated into Hexagon's Geosystems division and is expected to generate revenues of around 3 MEUR in 2025 with margins aligned with Hexagon's average levels. The transaction is expected to close by the end of Q2 2025, subject to regulatory approvals.